Clinical Infectious Diseases (CID) – Volume 61 Issue 11, December 1, 2015

Clinical Infectious Diseases (CID)
Volume 61 Issue 11 December 1, 2015
http://cid.oxfordjournals.org/content/current

.
Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator
Shamez N. Ladhani, Nick J. Andrews, Jo Southern, Christine E. Jones, Gayatri Amirthalingam, Pauline A. Waight, Anna England, Mary Matheson, Xilian Bai, Helen Findlow, Polly Burbidge,
Vasili Thalasselis, Bassam Hallis, David Goldblatt, Ray Borrow, Paul T. Heath, and Elizabeth Miller
Clin Infect Dis. (2015) 61 (11): 1637-1644 doi:10.1093/cid/civ695
Infants whose mothers received a pertussis-containing vaccine in pregnancy had high pre-immunization antibody concentrations, but responses to pertussis vaccine and CRM-conjugated vaccines were blunted after primary immunization.

.
Editorial Commentary: The Effect of Tdap Vaccination of Pregnant Women on the Subsequent Antibody Responses of Their Infants
James D. Cherry
Clin Infect Dis. (2015) 61 (11): 1645-1647 doi:10.1093/cid/civ700

.
Epidemiology and Risk Factors for Ebola Virus Disease in Sierra Leone—23 May 2014 to 31 January 2015
Patricia M. Dietz, Amara Jambai, Janusz T. Paweska, Zabulon Yoti, and Thomas G. Ksaizek
Clin Infect Dis. (2015) 61 (11): 1648-1654 doi:10.1093/cid/civ568
In Sierra Leone, 8056 persons had laboratory-confirmed Ebola virus disease between 23 May 2014 and 31 January 2015. Their median age was 28 years; 51.7% were female. Attending funerals and contact with sick persons were primary risk factors.

.
Immunization Costs and Programmatic Barriers at an Urban HIV Clinic
Ellen F. Eaton, Andrzej Kulczycki, Michael Saag, Michael Mugavero, and James L. Raper
Clin Infect Dis. (2015) 61 (11): 1726-1731 doi:10.1093/cid/civ637
A cost analysis at an urban, university-affiliated human immunodeficiency virus clinic revealed that providing 3 common vaccines (Gardasil, Prevnar, and Zostavax) to eligible patients would lead to a net loss of more than $90 000 in the first year.